We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
- Authors
Hecht, J Randolph; Mitchell, Edith; Chidiac, Tarek; Scroggin, Carroll; Hagenstad, Christopher; Spigel, David; Marshall, John; Cohn, Allen; McCollum, David; Stella, Philip; Deeter, Robert; Shahin, Seta; Amado, Rafael G
- Abstract
Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 5, p672
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.19.8135